ReviewEuropean journal of internal medicine2014
Management of nontuberculous mycobacterial infection in the elderly.
Review in European journal of internal medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01680822 (Treatment Outcomes in Patient With Nontuberculous Mycobacterial Disease in the University of Illinois Hospital & Health Sciences System), which is not on this map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Treatment Outcomes in Patient With Nontuberculous Mycobacterial Disease in the University of Illinois Hospital & Health Sciences System
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- High mortality in patients with Mycobacterium avium complex lung disease: a systematic review.BMC infectious diseases · 2018Pooled it
- Cancer risk in patients with nontuberculous mycobacterial pulmonary disease: a nationwide population-based cohort study.Respiratory research · 2026Article
- Age-Associated Inflammatory Monocytes Are Increased in Menopausal Females and Reversed by Hormone Replacement Therapy.Aging cell · 2025Article
- Considerations in the Diagnosis and Management of Bronchiectasis in Older Adults.Clinics in geriatric medicine · 2025Review
- Language and racial disparities in treatment initiation for patients with pulmonary non-tuberculous mycobacteria.BMC research notes · 2025Article
- Multimodal machine learning-based model for differentiating nontuberculous mycobacteria fromFrontiers in public health · 2025Article
- Case report: co-infection ofAME case reports · 2025Article
- Article
- Article
- Trends in Non-Tuberculous Mycobacterial Lung Disease and Treatment Outcomes in a Low-Tuberculosis Prevalence Setting: A Retrospective Analysis.Pathogens (Basel, Switzerland) · 2024Article
- Characterizing and correcting immune dysfunction in non-tuberculous mycobacterial disease.Frontiers in immunology · 2022Article
- Small vessel vasculitis secondary to Mycobacterium chelonae.Rheumatology international · 2021Review
- Variability in the Management of Adults With Pulmonary Nontuberculous Mycobacterial Disease.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- Comparison of Rifabutin-Based Versus Rifampin-Based Regimens for the Treatment ofFrontiers in pharmacology · 2021Article
- The Rise of Non-Tuberculosis Mycobacterial Lung Disease.Frontiers in immunology · 2020Review
- Socio-Economic and Environmental Factors Related to Spatial Differences in Human Non-Tuberculous Mycobacterial Diseases in the Czech Republic.International journal of environmental research and public health · 2019Article
- Nontuberculous mycobacterium M. avium infection predisposes aged mice to cardiac abnormalities and inflammation.Aging cell · 2019Article
- Diagnosis of nontuberculous mycobacterial disease in the era of surveillance chest CT scans.Infection · 2018Article
- Assessing Response to Therapy for Nontuberculous Mycobacterial Lung Disease: Quo Vadis?Frontiers in microbiology · 2018Review
- Non-cystic fibrosis bronchiectasis in the elderly: current perspectives.Clinical interventions in aging · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
Abstract
The incidence of nontuberculous mycobacteria (NTM) has increased over the last decades. Elderly people are more susceptible to NTM and experience increased morbidities. NTM incidence is expected to rise due to an increasing elderly population at least up to 2050. Given the importance of NTM infection in the elderly, an increasing interest exists in studying NTM characteristics in the aged population. In this review, we summarize the characteristics of NTM infection among elderly patients. We focus on epidemiology, clinical presentation, and treatment options of NTM in this age group. We highlight the differences in the diagnosis and treatment between rapid and slow growing mycobacterial infections. The current recommendation for treatment of NTM is discussed. We debate if in vitro susceptibility testing has a role in the treatment of NTM. Drug-drug interaction between antibiotics used to treat NTM and other medications, particularly warfarin, is another important issue that we discuss. Finally, we review the prognosis of NTM disease in elderly patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.